Global experience with ixabepilone in breast cancer
- PMID: 21554041
- DOI: 10.1586/era.11.41
Global experience with ixabepilone in breast cancer
Abstract
Ixabepilone approval in a number of countries across the world as monotherapy and in combination with capecitabine has led to widespread uptake in the later-line breast cancer setting. However, individualized data for ixabepilone in different ethnic groups are limited. Overall, data from small numbers of ethnic subgroups including Hispanic, Japanese and Chinese patients have revealed no clinically significant variation in the disposition, efficacy or tolerability of ixabepilone from that established in pivotal trials. Global use of ixabepilone, while usually along the lines of standard practice, may vary because of local regulatory decisions, clinical practice guidelines and cost considerations. Further information on the global patterns of use of ixabepilone will assist in optimizing the use of this novel therapy.
Similar articles
-
Advances in breast cancer treatment: the emerging role of ixabepilone.Expert Rev Anticancer Ther. 2010 Jan;10(1):23-32. doi: 10.1586/era.09.158. Expert Rev Anticancer Ther. 2010. PMID: 20014882 Review.
-
Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.Clin Ther. 2008 Sep;30(9):1590-617. doi: 10.1016/j.clinthera.2008.09.015. Clin Ther. 2008. PMID: 18840366 Review.
-
Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.Ann Pharmacother. 2008 Sep;42(9):1252-61. doi: 10.1345/aph.1L058. Epub 2008 Jul 22. Ann Pharmacother. 2008. PMID: 18648018 Review.
-
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.Breast Cancer Res Treat. 2010 Jun;121(2):261-71. doi: 10.1007/s10549-010-0824-0. Epub 2010 Mar 13. Breast Cancer Res Treat. 2010. PMID: 20229176 Review.
-
Ixabepilone: clinical role in metastatic breast cancer.Clin Breast Cancer. 2011 Jun;11(3):139-45. doi: 10.1016/j.clbc.2011.03.009. Epub 2011 Apr 20. Clin Breast Cancer. 2011. PMID: 21665133 Review.
Cited by
-
The microtubule stabilizer patupilone counteracts ionizing radiation-induced matrix metalloproteinase activity and tumor cell invasion.Radiat Oncol. 2013 Apr 30;8:105. doi: 10.1186/1748-717X-8-105. Radiat Oncol. 2013. PMID: 23631818 Free PMC article.
-
Trial watch: Chemotherapy with immunogenic cell death inducers.Oncoimmunology. 2013 Mar 1;2(3):e23510. doi: 10.4161/onci.23510. Oncoimmunology. 2013. PMID: 23687621 Free PMC article.
-
Trial Watch: Chemotherapy with immunogenic cell death inducers.Oncoimmunology. 2014 Jan 1;3(1):e27878. doi: 10.4161/onci.27878. Epub 2014 Mar 1. Oncoimmunology. 2014. PMID: 24800173 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical